Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials | Infectious Diseases | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.108.182. Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
1.
Dong  E, Du  H, Gardner  L.  An interactive web-based dashboard to track COVID-19 in real time.   Lancet Infect Dis. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1PubMedGoogle ScholarCrossref
2.
GitHub. Data from The New York Times based on reports from state and local health agencies. Accessed April 12, 2020. https://github.com/nytimes/covid-19-data
3.
National Clinical Trial Network Group Chairs. NCTN Group Chairs: cancer trials take backseat to clinical care amid COVID-19 pandemic. The Cancer Letter. Published April 10, 2020. Accessed May 7, 2020. https://cancerletter.com/articles/20200410_1/
4.
National Cancer Institute. Presentations from the 1st virtual joint meeting of NCI Board of Scientific Advisors and National Cancer Advisory Board. April 9, 2020. Accessed April 29, 2020. https://deainfo.nci.nih.gov/advisory/joint/0420/index.htm
5.
US Food and Drug Administration. FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic. Published March 2020. Accessed April 9, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic
6.
National Cancer Institute. Coronavirus guidance. Updated April 1, 2020. Accessed April 9, 2020. https://ctep.cancer.gov/investigatorResources/corona_virus_guidance.htm
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    Oncology
    June 1, 2020

    Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

    Author Affiliations
    • 1SWOG Cancer Research Network Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • 2SWOG Cancer Research Network Group Chair’s Office, Oregon Health and Science University Knight Cancer Institute, Portland
    • 3Columbia University Medical Center, New York, New York
    JAMA Netw Open. 2020;3(6):e2010651. doi:10.1001/jamanetworkopen.2020.10651

    Enrollment in clinical trials is key in advancing new treatments for patients with cancer. Poor accrual can result in trials that fail to complete or generate less timely research findings for patients in need of better therapies. The outbreak of coronavirus disease 2019 (COVID-19) has caused severe disruptions in care for many patients—especially patients with cancer, who are more susceptible to infections because of underlying malignant neoplasms or therapy—in an effort to reduce patient and staff exposure and to preserve resources. Given systemwide changes, some institutions in areas with high rates of COVID-19 have stopped all enrollment in interventional trials, while others have made minor changes. An important question is how the COVID-19 pandemic is associated with national enrollment in cancer clinical trials.

    ×